carvedilol / Generic mfg. - LARVOL DELTA

Cardioprotection without risk? meta-analysis of prophylactic agents in low-risk cancer patients on anthracyclines (ASH 2025) - "We included randomized controlled trials (RCTs) of prophylactic ACE inhibitors, ARBs, beta-blockers, statins, dexrazoxane, or SGLT2 inhibitors in adults without pre-existing cardiovascular risk factors...Agents studied included beta-blockers (nebivolol, carvedilol, bisoprolol), ACE inhibitors (ramipril), ARBs (telmisartan), and spironolactone. Treatment duration ranged from 4 months to 1 year; anthracycline doses reached up to 689 mg/m² (epirubicin) or 536 mg/m² (doxorubicin)...The protective benefit was greater in contexts involving higher cumulative anthracycline doses and concurrent cardiotoxic therapies such as trastuzumab...However, high heterogeneity limits firm conclusions. Given the moderate effect size and heterogeneity, further large-scale, well-formulated trials are essential to identify optimal cardioprotective agents and precise patient selection criteria."

Retrospective data • Breast Cancer • Congestive Heart Failure • Heart Failure • Oncology • Solid Tumor

Never change a winning team-liver stiffness measurement and platelet count as key surrogates for clinically significant portal hypertension. (PubMed, Hepatobiliary Surg Nutr) - No abstract available

Journal • Cardiovascular • Hypertension • Portal Hypertension

Pharmacological prevention in cardio-oncology: from bench-to-bedside. (PubMed, Heart Fail Rev) - "Neurohormonal blockers, including ACE inhibitors, ARBs, and β-blockers, constitute the foundation of prevention, although their efficacy varies: combinations such as ACEi/ARB with βB yield mixed outcomes, whereas carvedilol offers antioxidant benefits beyond β-blockade. Sacubitril/valsartan (ARNI) has demonstrated improvements in global longitudinal strain and LVEF preservation in the SARAH trial, albeit with associated hypotension risks. Aldosterone antagonists show potential, with spironolactone preserving LVEF and diastolic function, though eplerenone has not shown significant effects. Statins present conflicting data; the STOP-CA trial supports atorvastatin for LVEF preservation, while the PREVENT and SPARE-HF trials found no benefit. Emerging evidence suggests sodium-glucose cotransporter-2 inhibitors (SGLT2i), such as dapagliflozin and empagliflozin, as promising agents, with preclinical and early clinical data indicating cardioprotection through metabolic..."

Journal • Review • Cardiovascular • Hypotension • Metabolic Disorders • Oncology • ICOS

Potentiation of ryanodine receptor-mediated calcium release by MAPK is responsible for epidermal transformation and carcinogenesis. (PubMed, Proc Natl Acad Sci U S A) - "The β-blocker carvedilol inhibits EGF-promoted JB6 transformation, but the underlying mechanism is unknown...Human skin tissue microarray analysis confirmed spatial colocalization of phospho-ERK and RyR2 in the same tumor areas. Thus, potentiation of RyR-mediated Ca2+ release by MAPK is an important pathway leading to carcinogenesis."

Journal • Dermatitis • Oncology • EGF • KRAS • MAP2K1

Mitigating Doxorubicin-Induced Toxicity in Breast Cancer Treatment with In Situ pH-Sensitive Carvedilol-loaded Transbilosomes: In Vitro and In Vivo Characterization. (PubMed, J Drug Target) - "Furthermore, DRC-IPCT increased the levels of glutathione, superoxide dismutase, and catalase by 2.03-fold, 1.52-fold, and 1.94-fold, respectively. These findings indicate that the DRC-IPCT formulation is a promising therapy to prevent DIT-associated breast cancer."

Journal • Preclinical • Breast Cancer • Oncology • Solid Tumor • CAT

Availability and Affordability of Essential Antihypertensive Medicines in Public and Private Primary Care Drug Facilities in a 4th Class Municipality in the Philippines. (PubMed, Acta Med Philipp) - "While most medicines were deemed affordable in the private setting, there are still drugs such as carvedilol and enalapril, that need to be regulated. There is a need to strengthen the local pharmaceutical subsystem because it is essential to ensure safe, effective, and quality medicines in the local health system through adequate mobilization of resources."

Journal

Comparison of lipophilic and size-exclusion membranes: creating sink conditions with cyclodextrin. (PubMed, ADMET DMPK) - "This study aims to investigate the permeability differences of carvedilol between lipophilic (organic solvent) and size-exclusion membranes in the presence of 2-hydroxypropyl-beta-cyclodextrin in just the acceptor compartment or both sides of the membrane using in vitro side-by-side diffusion cell assays...It is also applicable when the solubilizing additive permeates slowly and has minimal influence on transport, such as with a size-exclusion membrane with a 1 kDa molecular weight cut-off. The model remains suitable if the additive is small enough in hydrodynamic size to permeate the membrane, but no concentration gradient exists to drive its transport, for example, with a 6 kDa size-exclusion membrane containing the same CD concentration on both sides of the membrane."

Journal

Beta-Blockers as Potential Adjuvants in Melanoma Treatment. (PubMed, Toxics) - "The effects of non-selective β-blockers (carvedilol and propranolol), β1 selective blockers (atenolol and metoprolol) and antineoplastics drugs (cisplatin and 5-fluorouracil) on the A375 melanoma cell line were studied, individually and in combined exposures, by assessing cell viability over a 72 h period. Metoprolol and carvedilol exhibited synergistic interactions with cisplatin at specific concentrations. Overall, the data highlight the concentration-dependent nature of mixture effects and support the potential application of β-blockers melanoma treatment."

Journal • Genetic Disorders • Melanoma • Oncology • Skin Cancer • Solid Tumor

Severe hypotensive transfusion reaction in a patient with liver dysfunction: A case report. (PubMed, Transfus Med) - "This case highlights the importance of recognising bradykinin-mediated HyTRs during FFP transfusion, especially in patients with liver dysfunction where impaired bradykinin degradation may contribute to accumulation. Prompt recognition, exclusion of alternative causes, and supportive management are crucial for favourable outcomes."

Journal • Acute Lung Injury • Allergy • Biliary Cancer • Cardiovascular • Diabetes • Fibrosis • Hematological Disorders • Hepatocellular Cancer • Hepatology • Hypertension • Hypotension • Immunology • Liver Cirrhosis • Liver Failure • Metabolic Disorders • Oncology • Pancreatic Cancer • Respiratory Diseases • Type 2 Diabetes Mellitus

Sleep deprivation and sleep intensity exert distinct effects on cerebral vasomotion and brain pulsations driven by the respiratory and cardiac cycles. (PubMed, PLoS Biol) - P1 | "We also examined the origin of LFPs through pharmacological vasodilation of the cerebral vasculature with the adrenergic antagonist carvedilol in a randomized, cross-over, double-blinded, placebo-controlled design (NCT03576664)...In summary, our findings indicate that heightened sleep pressure promotes vasomotion, whereas slow-wave-rich sleep amplifies respiration- and cardiac-driven brain pulsations, possibly indicating increased CSF flow to the brain. Together, this suggests that homeostatic sleep mechanisms are integral to human brain fluid dynamics and potentially also waste clearance."

Clinical • Journal

Acute cardiovascular complaints after recreational drug use (PubMed, Ned Tijdschr Geneeskd) - "For arrhythmia, labetalol, carvedilol, lidocaine and sodium bicarbonate can be considered. The use of beta-blockers is still under debate but should be considered in patients with heart failure with reduced ejection fraction. Therefore, always question patients with cardiovascular complaints about recreational drug use, know this changes management, and provide drug counselling."

Journal • Review • Acute Coronary Syndrome • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Pain

Causal Inference for First Non-Fatal Events With the Competing Risk of Death: A Principal Stratification Approach. (PubMed, Stat Med) - "Simulation studies are conducted to verify the reliability of our estimators. We illustrate the method using the Carvedilol Prospective Randomized Cumulative Survival trial, which involves heart-failure events."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Carvedilol Confers Neuroprotective Activity Through Modulating Ferroptosis Key Players and PINK1/PARKIN Mediated Mitophagy in an Experimental Parkinson's Rat Model. (PubMed, J Biochem Mol Toxicol) - "Carvedilol's protective effects extended to alleviate α-synuclein and upregulate tyrosine hydroxylase in the striata and substantia nigra leading to distinguished improvements of motor functions. To the best of our knowledge, this is the first study to highlight carvedilol's neuroprotective capacity against PD pathologies in terms of ferroptosis - mitophagy interaction as a novel therapeutic approach to tackle PD at earlier stages."

Journal • Preclinical • Cardiovascular • CNS Disorders • Movement Disorders • Parkinson's Disease • ACSL4 • CAT • GPX4

Scleroderma Renal Crisis (KIDNEY WEEK 2025) - "Other relevant history includes prior use of Ibuprofen 800 mg, 2-3 times a week for 1.5 months and workout supplemental protein...He received captopril within 24 hours of presentation given his history, which was titrated up to 62.5 mg, Q8 hourly. Carvedilol 25 BID and amlodipine 10 mg daily were also added for his BP...Newer agents like eculizamab and ravulizumab (complement C5 inhibitors) have shown some efficacy in SRC in small studies. SRC continues to be a grave complication of scleroderma. Prompt diagnosis and early BP control can prevent its progression but prognosis remains poor."

Acute Kidney Injury • Cardiovascular • Complement-mediated Rare Disorders • Eosinophilia • Hepatitis B • Hepatitis C • Human Immunodeficiency Virus • Hypertension • Immunology • Infectious Disease • Renal Disease • Rheumatology • Scleroderma • Systemic Sclerosis

Breast cancer progression in the presence of treated and untreated left ventricular dysfunction. (PubMed, Cardiooncology) - "Specific HF treatments can mitigate cancer growth in a mouse model of MI-induced LV dysfunction, with outcomes varying by treatment. These benefits occurred only with LV dysfunction, suggesting they result from changes in HF pathophysiology rather than direct drug effects on tumor cells. Restoration of immune signaling may contribute to these effects."

Journal • Breast Cancer • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction • Oncology • Solid Tumor • IFNG • STAT1

Lymphoid Malignancies in Shwachman-Diamond Syndrome: Incidence, Clinical Features, and Outcomes from the North American SDS Registry (ASH 2023) - "His course was complicated by febrile neutropenia, pleural effusion, deep vein thrombosis, and decreased cardiac ejection fraction requiring subsequent omission of doxorubicin and carvedilol initiation...He received 5 cycles of R-CHOP therapy, which was complicated by febrile neutropenia and S. aureus sepsis...He achieved complete remission of both malignancies after 2 cycles of cyclophosphamide, vincristine, prednisone, obinutuzumab, azacitidine, and venetoclax...He initiated therapy with steroids, doxorubicin, vinblastine, dacarbazine, and brentuximab vedotin and received focal radiation...Due to infectious complications and delayed count recovery after 2 cycles, despite chemotherapy dose reductions, he was transitioned to brentuximab and nivolumab... The incidence of lymphoma among patients with SDS is increased relative to the general population but is lower than the incidence of MDS or AML. Increased toxicity with standard therapies was observed in these patients...."

Clinical • Acute Myelogenous Leukemia • B Cell Lymphoma • Bone Marrow Transplantation • Cardiovascular • Classical Hodgkin Lymphoma • CNS Disorders • Dermatology • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Infectious Disease • Lymphoma • Mediastinal B Cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • Pulmonary Disease • Respiratory Diseases • Septic Shock • Thrombosis • Transplantation

A Rare Case of ANCA-Associated Vasculitis (AAV) with Concurrent Immune Complex (IC) Deposition (KIDNEY WEEK 2025) - "Case Description A 74-year old male with past medical history of prostate cancer (CA), non-small cell lung CA, basal cell CA, rheumatoid arthritis (on abatacept) and hypertension presented to the hospital with complaint of flank pain. He reported consuming 1.6-2g/day of ibuprofen. Home medications included nifedipine and carvedilol...He received induction treatment with rituximab, steroids and avacopan...However, the deposition of both IgG and IgA co-dominant deposits is still rare. In spite of his aggressive RPGN, we elected not to use cyclophosphamide given his recent malignancies."

Clinical • ANCA Vasculitis • Genito-urinary Cancer • Glomerulonephritis • Hypertension • IgA Nephropathy • Immunology • Inflammatory Arthritis • Lung Cancer • Lupus Nephritis • Nephrology • Non Small Cell Lung Cancer • Prostate Cancer • Renal Disease • Rheumatoid Arthritis • Rheumatology • Solid Tumor • Thrombosis • Vasculitis • MPO

Complement-Mediated Thrombotic Microangiography Presenting as Hypertensive Emergency and Kidney Failure (KIDNEY WEEK 2025) - "He was discharged on Carvedilol, Hydralazine, Nifedipine and Spironolactone...He was started on ravulizumab-cwvz with improvement in his Cr and BP...CM-TMA tends to fall lower on the differential, however early diagnosis and treatment is essential for treatment and prevention of worsening renal failure. This case also highlights the importance of access to care and the financial burdens that may limit or delay treatment."

Acute Kidney Injury • Anemia • Atypical Hemolytic Uremic Syndrome • Cardiovascular • Complement-mediated Rare Disorders • Hematological Disorders • Hypertension • Immunology • Nephrology • Renal Disease • Thrombocytopenia • Thrombocytopenic Purpura

Late-Onset Kidney Failure from Angiotensin Blockade: Combination Guideline-Directed Medical Therapy in CKD Must Be Individualized - How Concerning Is Late-Onset eGFR Decline with GDMT? A Patient's Wife Reacted Vigorously! (KIDNEY WEEK 2025) - "Case Report 80-yo male patient with hypertension, dilated cardiomyopathy, proteinuria and DM was on stable combination GDMT with Losartan 50 mg BID, Carvedilol 12.5 mg BID and Spironolactone 25 mg/d for over 4 years. Finally, we call for cautious excitement about the increasing availability of new “Cardiorenal protective agents". The physician’s oath to do no harm must remain our sacred mantra."

Clinical • Cardiomyopathy • Cardiovascular • Chronic Kidney Disease • Hypertension • Renal Disease

Resistant Hypertension in ANCA-Associated Vasculitis: Role for Aliskiren? (KIDNEY WEEK 2025) - "Despite receiving cyclophosphamide and methylprednisolone, he remained dialysis-dependent and was referred for renal transplant. He had multiple hypertensive emergency admissions despite a multi-drug regimen with nifedipine, telmisartan, carvedilol, eplerenone, clonidine, and hydralazine, and dry weight optimization...Studies are warranted to compare DRI efficacy against standard antihypertensives in similar clinical scenarios. The views expressed in this abstract are those of the author(s) and do not necessarily reflect the official policy of the Department of Defense or the U.S. Government."

ANCA Vasculitis • Cardiovascular • Glomerulonephritis • Hypertension • Inflammation • Lupus Nephritis • Nephrology • Renal Disease • Vasculitis • MPO

Hyperkalemia and Bradycardia in Dialysis: How Often Are We Missing Bradycardia, Renal Failure, Atrioventricular Nodal Blockade, Shock, and Hyperkalemia (BRASH)? (KIDNEY WEEK 2025) - "This was resolved with glycopyrrolate, ephedrine, and epinephrine...For the repeat surgery, carvedilol was held, and preoperatively, dialysis was performed with serum potassium of 3.4mEq/L...In ESKD patients with bradycardia, hyperkalemia, and AV nodal blockade, BRASH should be high on the differential. Early recognition and intervention can prevent complications, reduce risk, and improve outcomes."

Anesthesia • Cardiovascular • Chronic Kidney Disease • Coronary Artery Disease • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Nephrology • Obstructive Sleep Apnea • Renal Disease • Respiratory Diseases • Sleep Disorder

A Case of Probable Empagliflozin-Induced Psoriasis in a Patient with Diabetic Kidney Disease (KIDNEY WEEK 2025) - "Her medications included Empagliflozin started in February 2025, Carvedilol Furosemide &. Losartan...The patient was prescribed diphenhydramine for itching and clobetasol cream apllied twice daily to scaly lessions on affected areas...Two prior cases of psoriatic skin eruptions have been described with Dapagliflozin[3,4]...WE present the first case of Empagliflozin-induced psorisis in CKD patient. One study suggested no SGLT-2 had no impact on f psoriasis [5]"

Clinical • Atopic Dermatitis • Chronic Kidney Disease • Dermatitis • Dermatology • Dermatopathology • Diabetic Nephropathy • Immunology • Nephrology • Pruritus • Psoriasis • Renal Disease

Esophageal Variceal Bleed, an Unusual Presentation of Factor V Leiden Thrombophilia (ASH 2024) - "She was started on carvedilol 3.125 mg and low dose Eliquis 2.5 mg twice a day due to high risk for bleeding.Discussion : Factor V Leiden (FVL) results from a point mutation in the F5 gene, which encodes the factor V protein in the coagulation cascade...A study by Kouides et al showed that apixaban has equivalent efficacy in prevention of recurrent VTE but decreased risk of major and minor bleeding events compared with rivaroxaban...Complications can include esophageal variceal bleed and other sequalae of portal hypertension. Multidisciplinary approach is required for individual case including decision about anticoagulation."

Cardiovascular • Complement-mediated Rare Disorders • Gastroenterology • Genetic Disorders • Hematological Disorders • Hepatology • Immunology • Inflammatory Arthritis • Paroxysmal Nocturnal Hemoglobinuria • Portal Hypertension • Rare Diseases • Venous Thromboembolism • PROS1 • PRSS1

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Propranolol/Carvedilol Versus Atenolol/Bisoprolol/Sotalol (clinicaltrials.gov) - P=N/A | N=817337 | Completed | Sponsor: Brigham and Women's Hospital | Active, not recruiting ➔ Completed

Trial completion • Alzheimer's Disease • Cardiovascular • CNS Disorders • Hypertension

Dilated Cardiomyopathy in Adult Propionic Acidemia Improved by Adjustment of Nutrition and Heart Failure Treatment Drugs: A Case Report (SSIEM 2023) - "However, it exacerbated, and he was re- admitted and discharged after introducing carvedilol and pimobendane... In terms of changes before and after heart failure treatment, NTproBNP: 6858→51 pg/ml, chest CTR: 60.7→51.5%, improvement in abnormal electrocardiogram findings, left ventricular end-diastolic diameter (LVDd): 67/60→48/37 mm, left ventricular ejection fraction (EF): 27→51% and improvement in valve regurgitation in echocardiography were observed. The patient showed a favourable 5-year course, diuretic administration was reduced, and cardiac function significantly improved. Controlling acute and chronic heart failure with drugs and readjusting diet therapy according to improved cardiac function allowed the optimisation of the metabolic dynamics and maintain the improved dilated cardiomyopathy."

Case report • Clinical • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Developmental Disorders • Heart Failure • Infectious Disease • Mental Retardation